Abstract
Summary
Macular degeneration, also known as age-related macular degeneration (AMD or ARMD), is a medical condition which may result in blurred or no vision in the center of the visual field. Early on there are often no symptoms. Over time, however, some people experience a gradual worsening of vision that may affect one or both eyes. While it does not result in complete blindness, loss of central vision can make it hard to recognize faces, drive, read, or perform other activities of daily life. Visual hallucinations may also occur but these do not represent a mental illness.
LPI (LP Information)' newest research report, the “Macular Degeneration Treatment Industry Forecast” looks at past sales and reviews total world Macular Degeneration Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Macular Degeneration Treatment sales for 2023 through 2029. With Macular Degeneration Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Macular Degeneration Treatment industry.
This Insight Report provides a comprehensive analysis of the global Macular Degeneration Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Macular Degeneration Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Macular Degeneration Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Macular Degeneration Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Macular Degeneration Treatment.
The global Macular Degeneration Treatment market size is projected to grow from US$ 5821.5 million in 2022 to US$ 7524.9 million in 2029; it is expected to grow at a CAGR of 3.7% from 2023 to 2029.
United States market for Macular Degeneration Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Macular Degeneration Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Macular Degeneration Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Macular Degeneration Treatment players cover Bausch Health Companies, Allergan, Novartis, Pfizer, Bayer, Roche, Sanofi, Santen Pharmaceuticals and Regeneron Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Macular Degeneration Treatment market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Lucentis
Eylea
Avastin
Others
Segmentation by application
Hospitals
Eye Clinics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bausch Health Companies
Allergan
Novartis
Pfizer
Bayer
Roche
Sanofi
Santen Pharmaceuticals
Regeneron Pharmaceuticals
Kanghong Pharma
LPI (LP Information)' newest research report, the “Macular Degeneration Treatment Industry Forecast” looks at past sales and reviews total world Macular Degeneration Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Macular Degeneration Treatment sales for 2023 through 2029. With Macular Degeneration Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Macular Degeneration Treatment industry.
This Insight Report provides a comprehensive analysis of the global Macular Degeneration Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Macular Degeneration Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Macular Degeneration Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Macular Degeneration Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Macular Degeneration Treatment.
The global Macular Degeneration Treatment market size is projected to grow from US$ 5821.5 million in 2022 to US$ 7524.9 million in 2029; it is expected to grow at a CAGR of 3.7% from 2023 to 2029.
United States market for Macular Degeneration Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Macular Degeneration Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Macular Degeneration Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Macular Degeneration Treatment players cover Bausch Health Companies, Allergan, Novartis, Pfizer, Bayer, Roche, Sanofi, Santen Pharmaceuticals and Regeneron Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Macular Degeneration Treatment market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Lucentis
Eylea
Avastin
Others
Segmentation by application
Hospitals
Eye Clinics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bausch Health Companies
Allergan
Novartis
Pfizer
Bayer
Roche
Sanofi
Santen Pharmaceuticals
Regeneron Pharmaceuticals
Kanghong Pharma
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Macular Degeneration Treatment Market Size 2018-2029
2.1.2 Macular Degeneration Treatment Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Macular Degeneration Treatment Segment by Type
2.2.1 Lucentis
2.2.2 Eylea
2.2.3 Avastin
2.2.4 Others
2.3 Macular Degeneration Treatment Market Size by Type
2.3.1 Macular Degeneration Treatment Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Macular Degeneration Treatment Market Size Market Share by Type (2018-2023)
2.4 Macular Degeneration Treatment Segment by Application
2.4.1 Hospitals
2.4.2 Eye Clinics
2.4.3 Others
2.5 Macular Degeneration Treatment Market Size by Application
2.5.1 Macular Degeneration Treatment Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Macular Degeneration Treatment Market Size Market Share by Application (2018-2023)
3 Macular Degeneration Treatment Market Size by Player
3.1 Macular Degeneration Treatment Market Size Market Share by Players
3.1.1 Global Macular Degeneration Treatment Revenue by Players (2018-2023)
3.1.2 Global Macular Degeneration Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Macular Degeneration Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Macular Degeneration Treatment by Regions
4.1 Macular Degeneration Treatment Market Size by Regions (2018-2023)
4.2 Americas Macular Degeneration Treatment Market Size Growth (2018-2023)
4.3 APAC Macular Degeneration Treatment Market Size Growth (2018-2023)
4.4 Europe Macular Degeneration Treatment Market Size Growth (2018-2023)
4.5 Middle East & Africa Macular Degeneration Treatment Market Size Growth (2018-2023)
5 Americas
5.1 Americas Macular Degeneration Treatment Market Size by Country (2018-2023)
5.2 Americas Macular Degeneration Treatment Market Size by Type (2018-2023)
5.3 Americas Macular Degeneration Treatment Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Macular Degeneration Treatment Market Size by Region (2018-2023)
6.2 APAC Macular Degeneration Treatment Market Size by Type (2018-2023)
6.3 APAC Macular Degeneration Treatment Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Macular Degeneration Treatment by Country (2018-2023)
7.2 Europe Macular Degeneration Treatment Market Size by Type (2018-2023)
7.3 Europe Macular Degeneration Treatment Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Macular Degeneration Treatment by Region (2018-2023)
8.2 Middle East & Africa Macular Degeneration Treatment Market Size by Type (2018-2023)
8.3 Middle East & Africa Macular Degeneration Treatment Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Macular Degeneration Treatment Market Forecast
10.1 Global Macular Degeneration Treatment Forecast by Regions (2024-2029)
10.1.1 Global Macular Degeneration Treatment Forecast by Regions (2024-2029)
10.1.2 Americas Macular Degeneration Treatment Forecast
10.1.3 APAC Macular Degeneration Treatment Forecast
10.1.4 Europe Macular Degeneration Treatment Forecast
10.1.5 Middle East & Africa Macular Degeneration Treatment Forecast
10.2 Americas Macular Degeneration Treatment Forecast by Country (2024-2029)
10.2.1 United States Macular Degeneration Treatment Market Forecast
10.2.2 Canada Macular Degeneration Treatment Market Forecast
10.2.3 Mexico Macular Degeneration Treatment Market Forecast
10.2.4 Brazil Macular Degeneration Treatment Market Forecast
10.3 APAC Macular Degeneration Treatment Forecast by Region (2024-2029)
10.3.1 China Macular Degeneration Treatment Market Forecast
10.3.2 Japan Macular Degeneration Treatment Market Forecast
10.3.3 Korea Macular Degeneration Treatment Market Forecast
10.3.4 Southeast Asia Macular Degeneration Treatment Market Forecast
10.3.5 India Macular Degeneration Treatment Market Forecast
10.3.6 Australia Macular Degeneration Treatment Market Forecast
10.4 Europe Macular Degeneration Treatment Forecast by Country (2024-2029)
10.4.1 Germany Macular Degeneration Treatment Market Forecast
10.4.2 France Macular Degeneration Treatment Market Forecast
10.4.3 UK Macular Degeneration Treatment Market Forecast
10.4.4 Italy Macular Degeneration Treatment Market Forecast
10.4.5 Russia Macular Degeneration Treatment Market Forecast
10.5 Middle East & Africa Macular Degeneration Treatment Forecast by Region (2024-2029)
10.5.1 Egypt Macular Degeneration Treatment Market Forecast
10.5.2 South Africa Macular Degeneration Treatment Market Forecast
10.5.3 Israel Macular Degeneration Treatment Market Forecast
10.5.4 Turkey Macular Degeneration Treatment Market Forecast
10.5.5 GCC Countries Macular Degeneration Treatment Market Forecast
10.6 Global Macular Degeneration Treatment Forecast by Type (2024-2029)
10.7 Global Macular Degeneration Treatment Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Bausch Health Companies
11.1.1 Bausch Health Companies Company Information
11.1.2 Bausch Health Companies Macular Degeneration Treatment Product Offered
11.1.3 Bausch Health Companies Macular Degeneration Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Bausch Health Companies Main Business Overview
11.1.5 Bausch Health Companies Latest Developments
11.2 Allergan
11.2.1 Allergan Company Information
11.2.2 Allergan Macular Degeneration Treatment Product Offered
11.2.3 Allergan Macular Degeneration Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Allergan Main Business Overview
11.2.5 Allergan Latest Developments
11.3 Novartis
11.3.1 Novartis Company Information
11.3.2 Novartis Macular Degeneration Treatment Product Offered
11.3.3 Novartis Macular Degeneration Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Novartis Main Business Overview
11.3.5 Novartis Latest Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer Macular Degeneration Treatment Product Offered
11.4.3 Pfizer Macular Degeneration Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Pfizer Main Business Overview
11.4.5 Pfizer Latest Developments
11.5 Bayer
11.5.1 Bayer Company Information
11.5.2 Bayer Macular Degeneration Treatment Product Offered
11.5.3 Bayer Macular Degeneration Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Bayer Main Business Overview
11.5.5 Bayer Latest Developments
11.6 Roche
11.6.1 Roche Company Information
11.6.2 Roche Macular Degeneration Treatment Product Offered
11.6.3 Roche Macular Degeneration Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Roche Main Business Overview
11.6.5 Roche Latest Developments
11.7 Sanofi
11.7.1 Sanofi Company Information
11.7.2 Sanofi Macular Degeneration Treatment Product Offered
11.7.3 Sanofi Macular Degeneration Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Sanofi Main Business Overview
11.7.5 Sanofi Latest Developments
11.8 Santen Pharmaceuticals
11.8.1 Santen Pharmaceuticals Company Information
11.8.2 Santen Pharmaceuticals Macular Degeneration Treatment Product Offered
11.8.3 Santen Pharmaceuticals Macular Degeneration Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Santen Pharmaceuticals Main Business Overview
11.8.5 Santen Pharmaceuticals Latest Developments
11.9 Regeneron Pharmaceuticals
11.9.1 Regeneron Pharmaceuticals Company Information
11.9.2 Regeneron Pharmaceuticals Macular Degeneration Treatment Product Offered
11.9.3 Regeneron Pharmaceuticals Macular Degeneration Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Regeneron Pharmaceuticals Main Business Overview
11.9.5 Regeneron Pharmaceuticals Latest Developments
11.10 Kanghong Pharma
11.10.1 Kanghong Pharma Company Information
11.10.2 Kanghong Pharma Macular Degeneration Treatment Product Offered
11.10.3 Kanghong Pharma Macular Degeneration Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Kanghong Pharma Main Business Overview
11.10.5 Kanghong Pharma Latest Developments
12 Research Findings and Conclusion